152 related articles for article (PubMed ID: 7530943)
1. Role of alpha blockers in the treatment of BPH: a critical review of clinical results.
Von Heland M; Casale P
Arch Esp Urol; 1994 Nov; 47(9):873-81; discussion 881-2. PubMed ID: 7530943
[TBL] [Abstract][Full Text] [Related]
2. [Benign hypertrophy of the prostate: which treatment, for whom?].
Schulman C
Rev Med Brux; 1999 Sep; 20(4):A212-8. PubMed ID: 10523895
[TBL] [Abstract][Full Text] [Related]
3. Alpha adrenergic antagonists for the treatment of symptomatic BPH.
Lepor H
Int J Clin Pharmacol Ther Toxicol; 1989 Apr; 27(4):151-5. PubMed ID: 2469658
[TBL] [Abstract][Full Text] [Related]
4. The role of alpha-blockers in the management of acute urinary retention caused by benign prostatic obstruction.
Alan McNeill S
Eur Urol; 2004 Mar; 45(3):325-32. PubMed ID: 15036678
[TBL] [Abstract][Full Text] [Related]
5. Prostatic and extraprostatic alpha-adrenoceptors--contributions to the lower urinary tract symptoms in benign prostatic hyperplasia.
Andersson KE
Scand J Urol Nephrol Suppl; 1996; 179():105-11. PubMed ID: 8908675
[TBL] [Abstract][Full Text] [Related]
6. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting.
Mochtar CA; Kiemeney LA; Laguna MP; van Riemsdijk MM; Barnett GS; Debruyne FM; de la Rosette JJ
Urology; 2005 Feb; 65(2):300-5. PubMed ID: 15708042
[TBL] [Abstract][Full Text] [Related]
7. Alpha-adrenergic mechanisms in dynamics of benign prostatic hypertrophy.
Caine M
Urology; 1988 Dec; 32(6 Suppl):16-20. PubMed ID: 2462300
[TBL] [Abstract][Full Text] [Related]
8. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
9. Long-term results of medical treatment in benign prostatic hyperplasia.
Kim CI; Chang HS; Kim BK; Park CH
Urology; 2006 Nov; 68(5):1015-9. PubMed ID: 17095071
[TBL] [Abstract][Full Text] [Related]
10. [Uroselectivity of alpha-1 antagonism in the treatment of benign prostatic hypertrophy: on the pharmacologic concept of the clinical approach].
Jolliet P; Bourin M
Therapie; 1998; 53(1):61-6. PubMed ID: 9773101
[TBL] [Abstract][Full Text] [Related]
11. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
Roehrborn CG
BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681
[TBL] [Abstract][Full Text] [Related]
12. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk.
Emberton M; Zinner N; Michel MC; Gittelman M; Chung MK; Madersbacher S
BJU Int; 2007 Aug; 100(2):249-53. PubMed ID: 17617135
[TBL] [Abstract][Full Text] [Related]
13. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms.
Lowe FC
Clin Ther; 2004 Nov; 26(11):1701-13. PubMed ID: 15639685
[TBL] [Abstract][Full Text] [Related]
14. The emerging role of alpha antagonists in the therapy of benign prostatic hyperplasia.
Lepor H
J Androl; 1991; 12(6):389-94. PubMed ID: 1722795
[TBL] [Abstract][Full Text] [Related]
15. [Doksazozin "Cardura" in acute urinary retention caused by benign prostatic hyperplasia].
Perepanova TS; Kamalov AA; Siniukhin VN; Gorokhnov AV; Khazan PL; Orlova EV
Urologiia; 2001; (3):18-20. PubMed ID: 11505534
[TBL] [Abstract][Full Text] [Related]
16. [Current drug therapy of benign prostatic hyperplasia].
Schmidbauer CP; Madersbacher S
Wien Med Wochenschr; 1996; 146(8):161-4. PubMed ID: 8767400
[TBL] [Abstract][Full Text] [Related]
17. [Doxazosin treatment of disorders of the voiding phase in benign prostatic hyperplasia].
Esteban Fuertes M; Salinas Casado J; Virseda Chamorro M; Ramírez Fernández JC; Salomon Moh'd S; Luengo Alpuente S; Resel Estévez L
Arch Esp Urol; 1997 Dec; 50(10):1057-66. PubMed ID: 9494194
[TBL] [Abstract][Full Text] [Related]
18. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
[TBL] [Abstract][Full Text] [Related]
19. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
Naslund M; Eaddy MT; Hogue SL; Kruep EJ; Shah MB
Curr Med Res Opin; 2009 Nov; 25(11):2663-9. PubMed ID: 19757985
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of alfuzosin 10 mg once daily in the treatment of symptomatic benign prostatic hyperplasia.
Kuritzky L; Rosenberg MT; Sadovsky R
Int J Clin Pract; 2006 Mar; 60(3):351-8. PubMed ID: 16494652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
